Education
About Us
Working with TipRanks
Follow Us
ImmunoPrecise Antibodies (IPA)
NASDAQ:IPA
IPA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.27 - $1.40
Previous CloseN/A
Volume74.57K
Average Volume (3M)3.29M
Market Cap
$17.94M
Enterprise Value$15.29M
Total Cash (Recent Filing)C$6.20M
Total Debt (Recent Filing)C$14.39M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Jul 24, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding45,765,118
10 Day Avg. Volume421,818
30 Day Avg. Volume3,285,482
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.79
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.00Price Target Upside925.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
ImmunoPrecise Antibodies News
PremiumCompany Announcements
ImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody Discovery
PremiumCompany Announcements
ImmunoPrecise Antibodies Earnings Call Highlights Growth
PremiumCompany Announcements
ImmunoPrecise Antibodies Reports Q3 FY25 Financial Results---
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company completed an equity raise and converted the remaining balance of its debentures, ending the quarter with $12.9 million in cash and no long-term debt.
Insider ConfidenceInsiders recently completed 763,000 in open market share purchases, indicating confidence in the company's future.
PartnershipsA new $8-$10 million co-development partnership with a large biotech firm and strategic agreements for generative AI in drug development highlight growth potential.
Bears Say
Financial PerformanceThe company reported FY3Q25 revenues of C$6.2M and a net loss of C$0.66 per diluted share, compared to the consensus estimated revenues of C$7.0M and a net loss of C$0.08 per share.
Market ConditionsIPA shares have declined this year with a dip in the overall market and uncertainties related to potential drug tariffs and government R&D spending.
---
Ownership Overview
5.25% Insiders
0.02% Mutual Funds
3.64% Other Institutional Investors
91.09% Public Companies and
Individual Investors
IPA FAQ
What was ImmunoPrecise Antibodies’s price range in the past 12 months?
ImmunoPrecise Antibodies lowest stock price was $0.27 and its highest was $1.40 in the past 12 months.
What is ImmunoPrecise Antibodies’s market cap?
ImmunoPrecise Antibodies’s market cap is $17.94M.
When is ImmunoPrecise Antibodies’s upcoming earnings report date?
ImmunoPrecise Antibodies’s upcoming earnings report date is Jul 24, 2025 which is in 104 days.
How were ImmunoPrecise Antibodies’s earnings last quarter?
ImmunoPrecise Antibodies released its earnings results on Mar 28, 2025. The company reported -$0.464 earnings per share for the quarter, missing the consensus estimate of -$0.056 by -$0.408.
Is ImmunoPrecise Antibodies overvalued?
According to Wall Street analysts ImmunoPrecise Antibodies’s price is currently Undervalued.
Does ImmunoPrecise Antibodies pay dividends?
ImmunoPrecise Antibodies does not currently pay dividends.
What is ImmunoPrecise Antibodies’s EPS estimate?
ImmunoPrecise Antibodies’s EPS estimate is -0.04.
How many shares outstanding does ImmunoPrecise Antibodies have?
ImmunoPrecise Antibodies has 45,765,118 shares outstanding.
What happened to ImmunoPrecise Antibodies’s price movement after its last earnings report?
ImmunoPrecise Antibodies reported an EPS of -$0.464 in its last earnings report, missing expectations of -$0.056. Following the earnings report the stock price went down -11.364%.
Which hedge fund is a major shareholder of ImmunoPrecise Antibodies?
Currently, no hedge funds are holding shares in IPA
---
Company Description
ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
---
IPA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including strategic partnerships, financial strengthening, and substantial growth in AI and biologics, overshadowing concerns about increased operating expenses and broader industry challenges.Read More>---
IPA Stock 12 Month Forecast
Average Price Target
$4.00
▲(925.64% Upside)
Technical Analysis
Best Analysts Covering IPA
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-48.89%
reiterated a buy rating 11 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -48.89% per trade.
---